ARCT Arcturus Therapeutics Holdings Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
16:09
Sep 09
Sep 09
r/biotech_stocks
Binary OTC data and CF Phase 3 decision drive ARCT upside
Author argues Arcturus Therapeutics offers binary upside from two near-term catalysts: ARCT-810 OTC deficiency Phase 2 data expected later in September 2026 (with regulatory path disclosed for adults and pediatrics) and an ARCT-032 cystic fibrosis Phase 3 go/no-go decision in Q4 2026 that would unlock up to $40 million non-dilutive funding from Thermo Fisher. The bull case rests on a differentiated inhaled mRNA platform (biodegradable LNP, improved RNA purification, custom nebulizer) that management claims solved the safety/tolerability barrier that sank prior inhaled RNA programs, plus KOSTAIVE vaccine revenue funding the therapeutics pipeline without dilution. Author frames the next 3-6 months as potentially decisive for the company's trajectory. Main stated risk: clinical-stage biotech binary outcomes, where unfavorable data or decisions would hurt the stock.
ARCT
Arcturus Therapeutics Holdings Inc.
Long
1ST
—
—
About ARCT Investor Commentary
Across the available history and selected sources, Buzzberg tracks ARCT (Arcturus Therapeutics Holdings Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 33% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 3 total trade ideas tracked. Past 7 days, before deduplication: 2 other directions. Latest voices: u/Exact_Journalist_426.